Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Beijing Sunho Pharmaceutical Co FCF Margin %?
Beijing Sunho Pharmaceutical CoBJSE:920017 80 FCF Margin % is 17.39% as of Jun. 2026, which is 104% above its 10-year median of 8.52. GuruFocus rates BJSE:920017 with a GF Score™ of 80/100 and a GF Value™ of ¥15.19 (Fairly Valued). The stock has 2 warning signs investors should review. Among 987 Drug Manufacturers companies, Beijing Sunho Pharmaceutical Co ranks better than 79.64% on this metric.
The historical rank and industry rank for Beijing Sunho Pharmaceutical Co's FCF Margin % or its related term are showing as below:
BJSE:920017'
s FCF Margin % Range Over the Past 10 Years
Min: -24.73 Med: 8.52 Max: 25.81
Current: 15.18
During the past 10 years, the highest FCF Margin % of Beijing Sunho Pharmaceutical Co was 25.81%. The lowest was -24.73%. And the median was 8.52%.
BJSE:920017's FCF Margin % is ranked better than 79.64% of 987
companies
in the Drug Manufacturers industry
Industry Median: 3.36
vs BJSE:920017: 15.18
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Sunho Pharmaceutical Co FCF Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Sunho Pharmaceutical Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Sunho Pharmaceutical Co FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Sunho Pharmaceutical Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Beijing Sunho Pharmaceutical Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Sunho Pharmaceutical Co (BJSE:920017) has a FCF Margin % of 17.39% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beijing Sunho Pharmaceutical Co and its competitors. This is 104% above median its historical median of 8.52. According to the industry distribution chart, Beijing Sunho Pharmaceutical Co ranks #201 out of 987 companies in the Drug Manufacturers industry, placing it in the top 20.4%.
Is Beijing Sunho Pharmaceutical Co's FCF Margin % too high?
Beijing Sunho Pharmaceutical Co's current FCF Margin % of 17.39% is 104% above median its 10-year median of 8.52. The Drug Manufacturers industry median FCF Margin % is 3.36. Beijing Sunho Pharmaceutical Co's value of 17.39% is 417.6% above this industry median. Based on the distribution chart, Beijing Sunho Pharmaceutical Co ranks #201 out of 987 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Beijing Sunho Pharmaceutical Co has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Sunho Pharmaceutical Co's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Sunho Pharmaceutical Co ranks #201 out of 987 companies for FCF Margin %. This places Beijing Sunho Pharmaceutical Co in the top 20% of its industry — outperforming the majority of peers. The industry median FCF Margin % is 3.36. Beijing Sunho Pharmaceutical Co's value of 17.39% is 417.6% above this benchmark. While the company's 10-year median is 8.52 vs. the industry median of 3.36, Beijing Sunho Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 3.36, based on 987 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Sunho Pharmaceutical Co's current FCF Margin % of 17.39% is 417.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beijing Sunho Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 3.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Sunho Pharmaceutical Co's current FCF Margin % is 17.39%, which is 104% above median its own 10-year median of 8.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Sunho Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Sunho Pharmaceutical Co (BJSE:920017) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.19, compared to a current price of ¥15.67 — trading 3.2% above its estimated fair value. The current FCF Margin % is 17.39%, which is 104% above median its 10-year median of 8.52 and 417.6% above the Drug Manufacturers industry median of 3.36. Beijing Sunho Pharmaceutical Co's overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Beijing Sunho Pharmaceutical Co (BJSE:920017), the current FCF Margin % is 17.39% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Sunho Pharmaceutical Co (BJSE:920017) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Sunho Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.67 is trading 3.2% above its estimated GF Value™ of ¥15.19.
GuruFocus considers Beijing Sunho Pharmaceutical Co to be Fairly Valued.
Key valuation signals for BJSE:920017:
FCF Margin %: 17.39% (104% above median its 10-year median of 8.52)
GF Value™: ¥15.19 vs. price of ¥15.67 (3.2% above fair value)
Industry Position: 417.6% above the Drug Manufacturers median (#201 of 987)
No single metric tells the full story. See the BJSE:920017 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Sunho Pharmaceutical Co Ltd engages in the research and development, production, and sales of pharmaceutical preparations while providing CMC/CMO integrated services for pharmaceutical preparation manufacturers and drug R&D enterprises. The company produces small-volume injections, freeze-dried powder injections, hard capsules, tablets, and other products. The company's main products included: compound digestive enzyme capsules, piracetam (small injection and powder injection), and oxalic acid acetate.
80GF Score
Get the complete analysis for BJSE:920017
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920017 has been successfully added to your 
